Good morning, everyone, and how are you today? We are doing just fine, thank you, after a brief respite to observe ancient rituals. Now, though, we have returned to the usual routine of online meetings, calls, and deadlines. Some things are predictable, yes? So to cope, we are enjoying a cup of stimulation — chocolate raspberry is our flavor du jour — and we invite you to join us. Meanwhile, we have gathered a few items of interest to help you get moving on your own journey today, which we hope will be productive and meaningful. And of course, we encourage you to keep in touch. We are always on the prowl for new pen pals. …
An investigational Alzheimer’s disease treatment from Biogen and Eisai slowed the rate of cognitive decline by 27% in a clinical trial, meeting the goals of a closely tracked study and strengthening the case for regulatory approval as early as January, STAT reports. The positive result is welcome news for the millions of people living with Alzheimer’s and a big win for Eisai and Biogen, giving the companies a potential blockbuster product in the intravenous medicine, called lecanemab. For Biogen, which presided over the disastrous rollout of the Aduhelm treatment of Alzheimer’s, the potential approval of lecanemab presents a rare second chance at a multibillion-dollar market.
European drugmakers warned they may stop making some cheap generic medicines because of surging electricity costs and are calling for an overhaul of the way they are priced, the latest industry to seek help as the energy crisis deepens, Reuters writes. The generic industry lobbying group, Medicines for Europe, sent an open letter to European Union member states’ energy and health ministers ahead of their extraordinary EU Council meeting on Friday, calling for measures to ease the cost burden. Electricity prices have risen 10-fold for some drug factories in Europe and raw material costs have risen by between 50% and 160%, according to the letter.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect